Publications by authors named "A Geara"
Article Synopsis
- High-dose methotrexate (MTX) can lead to serious complications like acute kidney injury (AKI), neutropenia, and liver damage, but glucarpidase, an enzyme that breaks down MTX, shows potential benefits.
- In a study of 708 patients with MTX-AKI across 28 cancer centers, those receiving glucarpidase had a significantly higher chance of kidney recovery and faster recovery times compared to those who did not receive the treatment.
- Additionally, glucarpidase treatment was associated with lower rates of severe neutropenia and liver enzyme elevation, but there was no notable difference in mortality rates between the two groups.
Onconephrology, an emerging discipline nestled at the intersection of nephrology and oncology, has experienced remarkable growth over the past 15 years. This evolution has been punctuated by pivotal events, including establishing the American Society of Onconephrology, dedicated forums, and journals, highlighting its increasing significance. The clinical landscape of onconephrology is diverse, encompassing AKI in patients with cancer, toxicity from anticancer treatments, and a spectrum of electrolyte disorders, necessitating close collaboration between nephrologists and oncologists.
View Article and Find Full Text PDFBackground: During the COVID-19 pandemic, SARS-CoV-2 monoclonal antibodies for preexposure prophylaxis (SMA-PrEP) offered patients who were immunocompromised another option for protection. However, SMA-PrEP posed administrative, operational, and ethical challenges for health care facilities, resulting in few patients receiving them. Although the first SMA-PrEP medication, tixagevimab and cilgavimab, had its authorization revoked due to compromised in vitro efficacy, new SMA-PrEP medications are currently completing clinical trials.
View Article and Find Full Text PDF